Nazal Obaid, MD
Cardiovascular Disease · Portage, INNPI 1891797064
Payments from drug & device makers
Across 547 payments — averaging $30.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- W. L. Gore & Associates, Inc.$2K
- Philips North America LLC$1K
- Merck$895
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$814
- EKOS Corporation$731
- plus $9K from 44 others
What the payments were for
- Travel & lodging$1,5169%
- Food & beverage$14,86090%
- Education$730%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IGT D Peripheral$853
- GORE VIABAHN VBX Balloon Expandable Endo$755
- EKOSONIC$720
- GORE VIABAHN Endoprosthesis$464
- Impella$408
- ENTRESTO$358
- ENROUTE Transcarotid Neuroprotection System$300
- VERQUVO$250
- NEXLIZET$231
- NEXLETOL$231
- JARDIANCE$229
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$150
- ENROUTE Transcarotid Stent$150
- Indigo System$146
- WATCHMAN FLX$144
- WATCHMAN Access System$143
- Mitra Clip system$139
- GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis$128
- Watchman$127
- GORE EXCLUDER AAA Endoprosthesis$116
How this compares
$16,449 in reported general payments places this provider in the 75th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 266 | $307,619 |
| EntrestoSacubitril/Valsartan | 179 | $231,697 |
| XareltoRivaroxaban | 187 | $228,422 |
| MultaqDronedarone Hcl | 25 | $57,871 |
| JardianceEmpagliflozin | 42 | $44,976 |
| BrilintaTicagrelor | 56 | $41,422 |
| Repatha SureclickEvolocumab | 50 | $34,305 |
| FarxigaDapagliflozin Propanediol | 25 | $22,422 |
| NexlizetBempedoic Acid/Ezetimibe | 26 | $19,656 |
| Praluent PenAlirocumab | 19 | $9,477 |
| Amiodarone Hcl | 147 | $7,608 |
| Sildenafil Citrate | 13 | $7,307 |
| Metoprolol Succinate | 574 | $6,935 |
| VascepaIcosapent Ethyl | 19 | $6,591 |
| Dexlansoprazole DrDexlansoprazole | 17 | $6,591 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $229 | $307,619266 claims |
| NovartisEntresto | $2,226 | $231,697179 claims |
| Johnson & JohnsonXarelto | $569 | $228,422187 claims |
| AstraZenecaBrilinta, Farxiga | $553 | $63,84581 claims |
| Sanofi-aventis U.S. LLCMultaq | $362 | $57,87125 claims |
| Boehringer IngelheimJardiance | $689 | $44,97642 claims |
| Esperion Therapeutics, Inc.Nexlizet | $605 | $19,65626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Portage
- John McGintyRichmond$3.7M
- Steven SteinhublLafayette$2.4M
- Ravi BhagwatMunster$2.2M
- Mohan KesaniMunster$1.2M
- Vijay MehtaElkhart$925K
- William CollisFort Wayne$842K
- Atul ChughIndianapolis$775K
- Noel DasguptaIndianapolis$744K
- Wail AsfourMunster$736K
- Vijay RaoIndianapolis$706K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.